HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC
Condition(s):Intrahepatic CholangiocarcinomaLast Updated:March 28, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Intrahepatic CholangiocarcinomaLast Updated:March 28, 2024Recruiting
Condition(s):Chemotherapy-induced Nausea and Vomiting; Highly Emetogenic ChemotherapyLast Updated:March 26, 2024Not yet recruiting
Condition(s):Breast CancerLast Updated:March 26, 2024Not yet recruiting
Condition(s):Lung Cancer; EGFR Gene Mutation; Minimal Residual DiseaseLast Updated:March 21, 2024Not yet recruiting
Condition(s):Natural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeLast Updated:March 18, 2024Recruiting
Condition(s):Pancreatic CancerLast Updated:March 15, 2024Not yet recruiting
Condition(s):Gastric CancerLast Updated:March 15, 2024Recruiting
Condition(s):Intrahepatic CholangiocarcinomaLast Updated:March 15, 2024Not yet recruiting
Condition(s):NSCLC Stage IVLast Updated:March 15, 2024Not yet recruiting
Condition(s):Colon CancerLast Updated:March 8, 2024Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.